LTR Pharma (ASX:LTP) said real-world findings for its intranasal spray product for erectile dysfunction from a group of 147 participants support the product's efficacy, according to a Tuesday Australian bourse filing.

Outcomes were assessed using a patient-reported composite measure of improved erectile hardness and/or achieving penetration following treatment, the company said. The company added that 68%, or 100 of the total group of 147 participants, with a mean age of 65.6 years, all of whom had previously been treated with oral PDE5 inhibitors, reported improved erectile hardness and/or achieving penetration with the product.

Moreover, 62% of the group had a history of prostate cancer, and 59% had undergone prostatectomy, per the filing. Meanwhile, 64% of post-prostatectomy patients, or 56 of 87 participants, reported improved erectile hardness and/or achieving penetration with the product.

LTR Pharma's shares jumped nearly 12% in recent trading on Tuesday.